Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program

BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Here, we performed an integrated analysis of malignancy events from the tofacitinib phase 3 UC clinical development program (excluding nonmelanoma skin cancer [NMSC]). METHODS: Dat...

詳細記述

保存先:
書誌詳細
出版年:Inflamm Bowel Dis
主要な著者: Lichtenstein, Gary R, Rogler, Gerhard, Ciorba, Matthew A, Su, Chinyu, Chan, Gary, Pedersen, Ronald D, Lawendy, Nervin, Quirk, Daniel, Nduaka, Chudy I, Thorpe, Andrew J, Panés, Julian
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2020
主題:
Clinical Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128409/
https://ncbi.nlm.nih.gov/pubmed/32766762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izaa199
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料